CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 38 enrolled
Drug / intervention
4 mg CLS-TA Suprachoriodal Injectiondrug
Likely dose
4 mg CLS-TA Suprachoriodal Injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03097315
NCT03097315Phase 3Completed
CompareCT.gov

Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis

Clearside Biomedical, Inc.·interventional·Posted Mar 31, 2017·Updated Jun 23, 2021

In Brief

A Phase 3 clinical trial evaluating 4 mg CLS-TA Suprachoriodal Injection for Uveitis and 4 related conditions. Completed, enrolled 38 participants across 10 sites.

Detailed Summary

This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 31, 2017
Enrollment StartApr 4, 2017
Primary CompletionJan 24, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.3 years ago

Interventions

4 mg CLS-TA Suprachoriodal Injectiondrug

CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints